ELCC 2021 | TERAVOLT: outcomes for patients with COVID-19 and lung cancer
Marina Garassino, MD, University of Chicago, Chicago, IL, outlines the findings of a study using data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry investigating outcomes for patients with lung cancer and COVID-19. The study found that the mortality rate for patients with lung cancer and COVID-19 was around 32% and that immunotherapies and targeted agents do not impact patient outcomes. Dr Garassino recommends vaccination against COVID-19 for patients with lung cancer on the basis of these findings. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.
Disclosures
Marina Garassino has received personal fees or grants from AstraZeneca, MSD, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Inivata, Novartis, Pfizer, Roche, Takeda, Seattle Genetics, Mirati Therapeutics, Daiichi Sankyo, Bayer, GlaxoSmithKline S.p.A, Sanofi-Aventis,, Blueprint Medicine, Janssen and Regeneron Pharmaceuticals; and has received institutional fees or grants from Eli Lilly, Pfizer, AstraZeneca, MSD, BMS, Celgene, Incyte, MedImmune, Novartis, Pfizer, Roche, Tiziana Sciences, GlaxoSmithKline S.p.A, Spectrum Pharmaceuticals, Clovis, Merck Serono, Bayer, Sanofi-Aventis, Blueprint Medicine, Merck KGaA, Ipsen, Exelisis, Otsuka Pharma, Janssen and Spectrum Pharmaceuticals.
